Akebia Therapeutics (AKBA)

$1.13 0.06 (5.61%)

16:00 EST AKBA Stock Quote Delayed 30 Minutes

Why Is Akebia Therapeutics (AKBA) Stock Up 14% Today?

By William White, InvestorPlace Writer Jul 1, 2022

Akebia Therapeutics (AKBA) stock is taking off on Friday after the kidney treatment company revealed the return of rights for vadadustat.

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday

Akebia Therapeutics (AKBA) Stock Soars 18% Despite Lack of News

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday

Volume:

Previous Close -

Market Cap 197.23M

PE Ratio -1.28

EPS -0.88

Volume (Avg. Vol.) 2.99M

Day's Range $0.99 - $1.15

52-Week Range $0.24 - $2.93

Dividend & Yield N/A (N/A)

AKBA Stock Predictions, Articles, and Akebia Therapeutics News

From InvestorPlace
From the Web

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday

By William White, InvestorPlace Writer Jun 15, 2022

It's time for another breakdown of the biggest pre-market stock movers as we get ready for the opening bell on Wednesday!

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday

By William White, InvestorPlace Writer May 16, 2022

Welcome back and get ready for another busy week of trading as we start it off with the biggest pre-market stock movers for Monday!

7 Biotech Stocks With Key Catalysts in March

By Shanthi Rexaline Mar 9, 2022

These seven stocks have some key catalysts lined up for March with the potential to move their price actions in big ways.

7 Speculative Penny Stocks Worth a Roll of the Dice

By Josh Enomoto, InvestorPlace Contributor Feb 25, 2022

Under any circumstance, penny stocks are extremely risky. However, their under-the-radar profile could be intriguing right now.

7 Small-Cap Stocks to Buy From the Beat-Up Bargain Bin

By Chris Lau, InvestorPlace Contributor Oct 11, 2021

Unwilling to wait for catalysts, some investors threw these small-cap stocks into the garbage bin. But that doesn't mean they won't succeed.

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday

By William White, InvestorPlace Writer Jun 1, 2021

Welcome back from the holiday weekend and let's get right into it with a look at the biggest pre-market stock movers for Tuesday.

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday

By William White, InvestorPlace Writer Apr 29, 2021

Good morning! We're getting ready for another day of trading with a list of the top pre-market stock movers for Thursday.

5 “Strong Buy” Biotech Stocks With More Than 80% Upside

By Maya Sasson, Writer, TipRanks Nov 27, 2019

For investors seeking out the ultimate high-risk, high-reward stocks, look no further than the biotech industry.

5 Healthcare Stocks That Are Down, But Not Out!

By Josh Enomoto, InvestorPlace Contributor Aug 29, 2018

Tough headwinds have impacted several healthcare stocks, presenting opportunities for risk-tolerant speculators.

Akebia Therapeutics Inc (AKBA) and Babcock & Wilcox Enterprises Inc (BW) Lead 18 Investor Reports

By Fintel May 23, 2017

13D and 13G filings are windows into activist investor activities. We look at 18 notable filings....

AKBA stock jumps after FDA nod for GSK kidney disease therapy (NASDAQ:AKBA)

From Seeking Alpha Feb 2, 2023

Kidney-disease drug developer Akebia Therapeutics (AKBA) jumped in the morning hours Thursday after GSK (GSK) announced the FDA nod for anemia treatment Jesduvroq. Read the full story here.

AKBA stock on watch after licensing deal for ferric citrate product (NASDAQ:AKBA)

From Seeking Alpha Dec 28, 2022

Akebia Therapeutics (AKBA) announced Wednesday a deal to grant an exclusive license to Averoa SAS develop and sell ferric citrate in certain European markets. Read the full story here.

Akebia Therapeutics (NASDAQ:AKBA) update on kidney disease therapy

From Seeking Alpha Dec 22, 2022

Akebia Therapeutics (AKBA) got a response from the U.S. FDA to its appeal to the regulator's rejection of its treatment for anemia due to kidney disease. Read more on the response here.

H.C. Wainwright Keeps Their Hold Rating on Akebia Therapeutics (AKBA)

From TipRanks Nov 4, 2022

H.C. Wainwright analyst Ed Arce maintained a Hold rating on Akebia Therapeutics (AKBA – Research Report) today and set a price target of $1.25. The company&#8...

Analysts’ Opinions Are Mixed on These Healthcare Stocks: SQZ Biotechnologies (SQZ) and Akebia Therapeutics (AKBA)

From TipRanks Aug 5, 2022

Analysts have been eager to weigh in on the Healthcare sector with new ratings on SQZ Biotechnologies (

H.C. Wainwright Maintains a Hold Rating on Akebia Therapeutics (AKBA)

From TipRanks Aug 5, 2022

In a report released today, Ed Arce fro...

Akebia Therapeutics (AKBA)

Why Is Akebia Therapeutics (AKBA) Stock Up 14% Today?

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday

Akebia Therapeutics (AKBA) Stock Soars 18% Despite Lack of News

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday

11 Best Stocks to Buy for 2023

Louis Navellier's Total Grade

Is ? a BUY?

Louis Navellier's Total Grade

Louis Navellier's Total Grade

Fundamental Grade

Quantitative Grade

Akebia Therapeutics (AKBA)

11 Best Stocks to Buy for 2023

Louis Navellier's Total Grade

Is ? a BUY?

Louis Navellier's Total Grade

Louis Navellier's Total Grade

Fundamental Grade

Quantitative Grade

AKBA Stock Predictions, Articles, and Akebia Therapeutics News

Subscriber Sign in